N-Acetyl-L-leucine CAS 1188-21-2

1. N-Acetyl-L-leucine is an acetylated derivative of the amino acid leucine and is being developed as a drug (levacetylleucine) for neurological disorders, with approved use in France for vertigo (Tanganil) and recent FDA approval (Aqneursa) for Niemann-Pick disease type C .
2. N-Acetyl-L-leucine CAS 1188-21-2 acts as a prodrug that bypasses the L-type amino acid transporter (LAT1) used by leucine and is instead taken up by organic anion transporters (OAT1, OAT3) and monocarboxylate transporter type 1 (MCT1), enabling tissue distribution and entry into metabolic pathways .
3. N-Acetyl-L-leucine has demonstrated neuroprotective effects in preclinical models, improving functional recovery and attenuating cortical cell death and neuroinflammation after traumatic brain injury in mice through partial restoration of autophagy flux .
4. Clinical trials have shown significant reductions in neurologic signs and symptoms in Niemann-Pick disease type C (SARA score improvement of -1.97 points vs. -0.60 with placebo), and ongoing studies are evaluating efficacy in ataxia-telangiectasia, GM2 gangliosidoses, and other neurodegenerative conditions .

1. N-Acetyl-L-leucine powder must be stored at -20°C for long-term stability (up to 3 years) or at 4°C for up to 2 years; solutions should be stored at -80°C for up to 6 months or -20°C for 1 month, protected from moisture .
2. N-Acetyl-L-leucine CAS 1188-21-2 is soluble in DMSO (≥20 mg/mL) and ethanol (34 mg/mL) but insoluble in water; stock solutions should be prepared in tightly sealed vials and used within 1 month at -20°C, avoiding repeated freeze-thaw cycles .
3. Levacetylleucine may cause embryo-fetal harm during pregnancy based on animal studies; females of reproductive potential should use effective contraception during treatment and for 7 days after the last dose .
4. N-Acetyl-L-leucine CAS 1188-21-2 inhibits P-glycoprotein (P-gp) efflux transporter; caution is advised when coadministered with P-gp substrates (e.g., digoxin, dabigatran, afatinib) as levels may increase, requiring monitoring for adverse effects .

1. Isolate the spill area, ensure adequate ventilation, and wear full personal protective equipment including chemical-resistant gloves, safety goggles, and suitable dust respirator when N-Acetyl-L-leucine is released.
2. Collect N-Acetyl-L-leucine CAS 1188-21-2 by sweeping or vacuuming without creating dust using non-sparking tools, and place into suitable closed containers for disposal.
3. Avoid creating dust clouds during cleanup to prevent respiratory exposure; prevent the product from entering drains or water courses as discharge into the environment should be avoided.
4. Dispose of collected material according to local, state, and federal environmental regulations through licensed chemical destruction or controlled incineration; the compound is not classified as hazardous goods for transport (IATA, IMDG, DOT).

1. N-Acetyl-L-leucine is not classified as highly flammable but may decompose under fire conditions, emitting toxic fumes including carbon monoxide, carbon dioxide, and nitrogen oxides (NOx).
2. Use N-Acetyl-L-leucine CAS 1188-21-2 water spray, dry chemical powder, carbon dioxide, or alcohol-resistant foam to extinguish fires involving the product.
3. Firefighters should wear self-contained breathing apparatus in pressure-demand, MSHA/NIOSH approved, and full protective gear when handling burning N-Acetyl-L-leucine due to hazardous decomposition gases generated by thermal decomposition.
4. During combustion, may emit irritant and toxic fumes; move containers from the fire area if safe to do so, cool exposed containers with water spray from a protected location, and contain fire runoff to prevent environmental contamination.